TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these infe...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy, Warren, Sarah, MacBeth, Kyle J., Meggendorfer, Manja, Haferlach, Torsten, Boettcher, Steffen, Ebert, Benjamin L., Al Ali, Najla H., Lancet, Jeffrey E., Cleveland, John L., Padron, Eric, List, Alan F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731792/
https://ncbi.nlm.nih.gov/pubmed/32730593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006158
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg